Crescent Biopharma (CBIO) Retained Earnings (2013 - 2026)
Crescent Biopharma (CBIO) reported Retained Earnings of -$195.1 million for Q1 2026, up 60.72% year-over-year from -$121.4 million in Q1 2025, and down 13.56% quarter-over-quarter from -$171.8 million in Q4 2025.
Crescent Biopharma (CBIO) Retained Earnings (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has 14 years of Retained Earnings data on file, last reported at -$195.1 million in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$195.1 million, up 60.72% year-over-year; the trailing twelve-month figure through Mar 2026 was -$195.1 million (up 60.72% YoY), and the FY2025 annual result was -$171.8 million, down 861.6% from the prior year.
- Retained Earnings eased to -$195.1 million in Q1 2026 per CBIO's latest filing, from -$171.8 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$17.9 million in Q4 2024 and troughed at -$496.7 million in Q1 2025.
- A 5-year average of -$343.3 million and a median of -$419.6 million in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings surged 96.09% in 2024, then sank 861.6% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$419.6 million in 2022, then slipped by 8.79% to -$456.5 million in 2023, then surged by 96.09% to -$17.9 million in 2024, then slumped by 861.6% to -$171.8 million in 2025, then slipped by 13.56% to -$195.1 million in 2026.
- Business Quant data shows CBIO's Retained Earnings at -$195.1 million in Q1 2026, -$171.8 million in Q4 2025, and -$79.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Crescent Biopharma | 486.92 Mn | 297.76 Mn | - | -195.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -195.10 Mn |
| Dec 31, 2025 | -171.81 Mn |
| Sep 30, 2025 | -79.41 Mn |
| Jun 30, 2025 | -54.80 Mn |
| Mar 31, 2025 | -496.71 Mn |
| Dec 31, 2024 | -17.87 Mn |
| Sep 30, 2024 | -487.14 Mn |
| Jun 30, 2024 | -477.32 Mn |
| Mar 31, 2024 | -467.22 Mn |
| Dec 31, 2023 | -456.49 Mn |
| Sep 30, 2023 | -447.40 Mn |
| Jun 30, 2023 | -438.20 Mn |
| Mar 31, 2023 | -429.90 Mn |
| Dec 31, 2022 | -419.59 Mn |
| Sep 30, 2022 | -409.34 Mn |
| Jun 30, 2022 | -400.82 Mn |
| Mar 31, 2022 | -387.55 Mn |
| Dec 31, 2021 | -372.90 Mn |
| Sep 30, 2021 | -355.48 Mn |
| Jun 30, 2021 | -338.14 Mn |